Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
134 hedge funds and large institutions have $220M invested in Sucampo Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 44 reducing their positions, and 34 closing their positions.
296% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $467K
23% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 44
10% less funds holding
Funds holding: 149 → 134 (-15)
41% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 34
43% less capital invested
Capital invested by funds: $383M → $220M (-$163M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.42M |
| 2 |
Morgan Stanley
New York
|
+$2.59M |
| 3 |
QI
QS Investors
New York
|
+$2.54M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$2.21M |
| 5 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.69M |
| 2 |
GAM
Gotham Asset Management
New York
|
-$3.78M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$3.62M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.45M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$3.33M |
SCMP Hedge Fund Activity: Q1 2016 in Review
134 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q1 2016, worth a combined $220M — down 43% from $383M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of SCMP and 20 opened new positions — a net loss of 14 holders — while 44 trimmed existing stakes and 54 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.42M. The largest seller was State Street, cutting an estimated $8.69M.
- 134 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q1 2016, down from 149 in Q4 2015.
- Funds reported $220M of Sucampo Pharmaceuticals, Inc. stock for Q1 2016, down 43% quarter-over-quarter.
- 20 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q1 2016 and 34 closed out, a net change of -14 holders.
- The largest Sucampo Pharmaceuticals, Inc. buyer in Q1 2016 was Renaissance Technologies, an estimated $3.42M added.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q1 2016 was State Street, an estimated $8.69M sold.
Based on aggregated 13F filings for Q1 2016.